Zhengning Lin, Ph.D.

atai Life Science

Zhengning Lin is a statistical leader with extensive experience and in-depth technical skills in identifying and solving challenging problems in clinical development and rare diseases. He is a key contributor and leader for strategic planning with critical input to address clinical and regulatory challenges. He is currently serving as VP of Biostatistics at atai Life Science.

Zhengning has close to 30 years of working experience in the biopharmaceutical industry, including over 12 years in CNS and neuroscience at Novartis and Eisai Pharmaceuticals, and over 4 years in metabolism (including diabetes) and other therapeutic areas at Sanofi-Aventis. He moved into the biotech industry with a focus of rare diseases in 2012 as VP of Biometrics at InterMune Inc. (2012-2015), and Executive Director of Biostatistics at BioMarin (2015-2016).

Zhengning holds a PhD in statistics and decision science from Duke University, with multiple first authored papers in clinical statistics, pharmacodynamic modeling, and reliability.